Physician profile
Sara B Blake
NPI 1801951942
$1,573.39
in general payments reported to CMS, 2019-2025
21 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $49.09 · 2021: $19.60 · 2022: $355 · 2023: $329 · 2024: $221 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.73 | 2019-2024 | Liletta, Orilissa, Lo Loestrin Fe |
| Biogen, INC. | $255.70 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $166.59 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $87.43 | 2022-2025 | Slynd |
| Myriad Genetic Laboratories, INC. | $82.52 | 2024 | Myrisk |
| Allergan, INC. | $73.12 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $70.21 | 2023 | Myfembree |
| Axonics, INC. | $68.35 | 2023 | Bulkamid |
| Pfizer INC. | $62.90 | 2023-2025 | |
| Millicent US INC | $51.47 | 2025 | Femlyv, Intrarosa, Femring |
| Organon LLC | $49.88 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $48.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $46.05 | 2019 | |
| Hologic Sales and Service, LLC | $43.48 | 2022-2024 | Acessa Provu System, Coolseal Generator |
| Novo Nordisk INC | $39.84 | 2022-2023 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $19.76 | 2025 | Arista |
| Medtronic, INC. | $18.55 | 2024 | Truclear |
| Daiichi Sankyo INC. | $17.62 | 2019 | |
| Covidien LP | $12.71 | 2019 | |
| Therapeuticsmd, INC. | $11.46 | 2020 | |
| Zyla Life Sciences, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.